|Project Title||Buprenorphine Product Use|
Sunday, November 9, 2014
Modular program-based one-time assessment use of Buprenorphine products both separately and as one drug category among all members (Overall) as well as those with a pre-existing diagnosis found in one of three composite categories: addiction-related diagnoses (16 codes), pain-related diagnoses (22 codes), and other defined diagnoses (8 codes). The query was run against the Mini-Sentinel Distributed Database (MSDD) for the time period of January 1, 2009 through December 31, 2010. Modular programs are adaptable standardized programs. Results were generated using Modular Program 2, version 3.1; click here for more information. Queries were distributed in February 15, 2010. This report includes data from 4 Data Partners.
If you are using a web page screen reader and are unable to access this document, please contact the Mini-Sentinel Operations Center for assistance by clicking on the Submit Comments link above or sending an email requesting assistance to email@example.com.
The information contained on this website is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Please read the disclaimer.
|Population / Cohort||
All individuals with pre-existing codes in addiction or pain
January 1, 2009 - December 31, 2010
Mini-Sentinel Distributed Database (MSDD)
- Vaccines, Blood & Biologics
- Devices and Radiologic Health